Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tripos International, a provider of drug discovery informatics products and services, has completed the acquisition of Pharsight, a provider of software, strategic and regulatory services designed to optimize clinical drug development.
Subscribe to our email newsletter
The transaction, valued at approximately $57 million, moves Pharsight into the Tripos portfolio. As a Tripos portfolio company, Pharsight will continue to develop and market integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
Pharsight’s goal will continue to be one of helping customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Jim Hopkins, president and CEO of Tripos, said: “We’re excited to add Pharsight to the Tripos family. By acquiring Pharsight, we expect to provide our customers with important new products, key enabling technologies and scientific expertise, and to expedite the flow of information throughout discovery and development.”